In Person Special Seminar: Connexin 43: A New Player in Duchenne Muscular Dystrophy and Associated Cardiomyopathy
Diego Fraidenraich, Ph.D., FAHA
Associate Professor
Cell Biology and Molecular Medicine
New Jersey Medical School
Rutgers University
In Person Seminar: Connexin 43: A New Player in Duchenne Muscular Dystrophy and Associated Cardiomyopathy
Date: Jan. 5, 2023
Time: 11 a.m.
Location: Room R3012, 2 Riverside Circle
About this Seminar
Aberrant expression of the cardiac gap junction protein connexin-43 (Cx43) has been suggested as playing a role in the development of cardiac disease in the mdx mouse model of Duchenne muscular dystrophy (DMD); however, a mechanistic understanding of this association is lacking. Here, Dr. Fraidenraich and his team identified a reduction of phosphorylation of Cx43 serines S325/S328/S330 in human and mouse DMD hearts. The team hypothesized that hypophosphorylation of Cx43 serine-triplet triggers pathological Cx43 redistribution to the lateral sides of cardiomyocytes (remodeling). Therefore, they generated knockin mdx mice in which the Cx43 serine-triplet was replaced with either phospho-mimicking glutamic acids (mdxS3E) or nonphosphorylatable alanines (mdxS3A). The mdxS3E, but not mdxS3A, mice were resistant to Cx43 remodeling, with a corresponding reduction of Cx43 hemichannel activity. MdxS3E cardiomyocytes displayed improved intracellular Ca2+ signaling and a reduction of NADPH oxidase 2 (NOX2)/ROS production. Furthermore, mdxS3E mice were protected against inducible arrhythmias, related lethality, and the development of cardiomyopathy. Inhibition of microtubule polymerization by colchicine reduced both NOX2/ROS and oxidized CaMKII, increased S325/S328/S330 phosphorylation, and prevented Cx43 remodeling in mdx hearts. Together, these results demonstrate a mechanism of dystrophic Cx43 remodeling and suggest that targeting Cx43 may be a therapeutic strategy for preventing heart dysfunction and arrhythmias in DMD patients.
You May Also Be Interested In...
-
Home Item
The Metabolic Switch in Development and Degeneration , homeDec. 12, 2025, 11:00 a.m. | Elizabeth Jonas, M.D., Harvey and Kate Cushing Professor of Internal Medicine (Endocrinology), Yale School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Neurobiology Research
-
Home Item
Innovative Strategies for Overcoming Challenges in Brain Tumor Treatment , homeJan. 16, 2026, 11:00 a.m. | Kristin Huntoon, Ph.D., D.O., Assistant Professor, Department of Neurosurgery, University of Arizona | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center – Roanoke
-
Home Item
Maury Strauss Distinguished Public Lecture , homeJan. 22, 2026, 5:30 p.m. (Reception at 5 p.m.) | Holly Ingraham, Ph.D., Professor, Cellular and Molecular Pharmacology; Elected Member, National Academy of Sciences | Maury Strauss Distinguished Public Lecture
-
Home Item
Policies to Reduce Ultra-processed Foods: Lessons From Around the Globe , homeJan. 30, 2026, 11:00 a.m. | Lindsey Smith Taillie, Ph.D., MPH, Associate Professor of Nutrition, Associate Chair of Nutrition, Gillings School of Global Public Health, University of North Carolina, Chapel Hill | Co-Sponsored by the Fralin Biomedical Research Institute Center for Health Behaviors Research and Addiction Recovery Research Center
-
Home Item
AI and Agentic AI: Opportunities for How We Work, Care, Discover, and Share , homeFeb. 5, 2026, 5:30 p.m. (Reception at 5 p.m.) | Vivian S. Lee, M.D., Ph.D., M.B.A., Executive Fellow, Harvard Business School; Senior Lecturer, Harvard Medical School; Elected Member, National Academy of Medicine | Maury Strauss Distinguished Public Lecture
-
Home Item
Early Childhood Brain Development and Risk for Schizophrenia , homeFeb. 13, 2026, 11 a.m. | John Gilmore, M.D., Eure Distinguished Professor and Vice Chair for Research, Department of Psychiatry, University of North Carolina School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research